Sridhar Viswanathan, Ph.D., is the senior vice president of process sciences and manufacturing operations. Dr. Viswanathan previously served as vice president of process development and manufacturing operations for Perseid Therapeutics, a joint venture between Maxygen and Astellas that was subsequently acquired by Astellas. He was responsible for all internal process development and external manufacturing operations at contract manufacturing organizations for advancing CTLA4-Ig Fc fusion products for autoimmune disease and organ transplant rejection. Before joining Perseid, Dr. Viswanathan spent several years at Maxygen directing process development and clinical manufacturing for next-generation biologics programs, including PEGylated interferon alpha, PEG-G-CSF and FVIIa. Prior to this, he held positions at Coulter Pharmaceutical, Bayer Corporation and Genentech. He received his doctorate in biochemistry from the University of Mississippi Medical Center and completed postdoctoral training at Rockefeller University and Stanford University.